TIDMAVCT

Avacta Group PLC

05 May 2017

5 May 2017

Avacta Group plc

("Avacta" or "the Group" or "the Company")

Avacta to Present at the Hardman Private Investor Forum

Avacta Group plc (AIM: AVCT), the developer of Affimer(R) biotherapeutics and research reagents, is pleased to announce that its Chief Executive, Alastair Smith, will be presenting at the Hardman Private Investor Forum on Tuesday 9(th) May in London at the University of Liverpool, 33 Finsbury Square, EC2A 1AG.

The evening event, which begins with registration at 17:30, provides an opportunity for investors to hear about the Company's Affimer(R) technology, its development plans and to discuss these with Alastair, Philippe Cotrel, the Company's Chief Commercial Officer, and with Dr Trevor Nicholls, Chairman of the Board.

ENDS

NOTES

For further information from Avacta Group plc, please contact:

 
 Avacta Group plc                          Tel: +44 (0) 
  Alastair Smith, Chief Executive           844 414 0452 
  Officer                                   www.avacta.com 
  Tony Gardiner, Chief Financial 
  Officer 
 finnCap Ltd                               Tel: +44 (0) 
  Geoff Nash / Giles Rolls - Nominated      207 220 0500 
  Adviser                                   www.finncap.com 
  Tim Redfern / Alice Lane - Corporate 
  Broking 
                                            Tel: +44 (0) 
  WG Partners                               203 705 9318 
  Nigel Birks / Nigel Barnes                Tel: +44 (0) 
  David Wilson / Claes Spang                203 705 9217 
                                            www.wgpartners.co.uk 
 Zyme Communications (Trade and            Tel: +44 (0)7787 
  Regional Media)                           502 947 
  Katie Odgaard                             katie.odgaard@zymecommunications.com 
 
  FTI Consulting (Financial Media           Tel: +44 (0) 
  and IR)                                   203 727 1000 
  Simon Conway / Natalie Garland-Collins    avacta@fticonsulting.com

About Avacta Group plc (www.avacta.com)

Avacta's principal focus is on its proprietary Affimer(R) technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.

Affimer technology has been designed to address many of the negative performance issues of antibodies, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of targets.

Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRALLFEEEIISIID

(END) Dow Jones Newswires

May 05, 2017 02:01 ET (06:01 GMT)

Avacta (LSE:AVCT)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Avacta Charts.
Avacta (LSE:AVCT)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Avacta Charts.